SAN MATEO, Calif. and SINGAPORE, Nov. 20, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, will participate in a fireside discussion at the Piper Sandler Healthcare Conference. The conference will be held from November 28 to 30, 2023, in-person at the Lotte New York Palace Hotel, in New York.
35TH Annual Piper Sandler Healthcare Conference Participation Information
Format: Fireside discussion
Presenter: Carl Firth, CEO, ASLAN Pharmaceuticals
Date: Wednesday, November 29, 2023
Time: 11:30 AM ET
A replay of the fireside discussion will be made available on the Investor Relations section of ASLAN’s website.
Management will also be available for one-on-one meetings with investors during the time of the conference. Please contact your representative at Piper Sandler to schedule a meeting.
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is developing eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor in moderate-to-severe atopic dermatitis (AD) with the potential to improve upon current biologics used to treat allergic disease, and has reported positive topline data from a Phase 2b dose-ranging study in moderate-to-severe AD patients. ASLAN is also developing farudodstat, a potent oral inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) as a potential first-in-class treatment for alopecia areata (AA) in a Phase 2a, proof-of-concept trial with an interim readout expected in 1Q 2024. ASLAN has teams in San Mateo, California, and in Singapore. For additional information please visit the Website or follow ASLAN on LinkedIn.
Media and IR contacts
| Emma Thompson Spurwing Communications Tel: +65 6206 7350 Email: This email address is being protected from spambots. You need JavaScript enabled to view it. | Ashley R. Robinson LifeSci Advisors, LLC Tel: +1 (617) 430-7577 Email: This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$0.60 |
| Daily Volume: | 0 |
| Market Cap: | US$1.700M |
May 09, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
